CL2020002768A1 - Métodos de diagnóstico de enfermedades mediante citometría de microflujos - Google Patents
Métodos de diagnóstico de enfermedades mediante citometría de microflujosInfo
- Publication number
- CL2020002768A1 CL2020002768A1 CL2020002768A CL2020002768A CL2020002768A1 CL 2020002768 A1 CL2020002768 A1 CL 2020002768A1 CL 2020002768 A CL2020002768 A CL 2020002768A CL 2020002768 A CL2020002768 A CL 2020002768A CL 2020002768 A1 CL2020002768 A1 CL 2020002768A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- μfcm
- disease
- diagnosing diseases
- disclosed
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1431—Signal processing the electronics being integrated with the analyser, e.g. hand-held devices for on-site investigation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
- G06N20/10—Machine learning using kernel methods, e.g. support vector machines [SVM]
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
- G06N20/20—Ensemble learning
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
- G06N3/09—Supervised learning
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
- G06N3/0985—Hyperparameter optimisation; Meta-learning; Learning-to-learn
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/01—Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N2015/0038—Investigating nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1488—Methods for deciding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/04—Architecture, e.g. interconnection topology
- G06N3/045—Combinations of networks
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/12—Computing arrangements based on biological models using genetic models
- G06N3/126—Evolutionary algorithms, e.g. genetic algorithms or genetic programming
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N7/00—Computing arrangements based on specific mathematical models
- G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Software Systems (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Computing Systems (AREA)
- Mathematical Physics (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Computation (AREA)
- General Engineering & Computer Science (AREA)
- Artificial Intelligence (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Computational Linguistics (AREA)
- Signal Processing (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se revelan los métodos de diagnóstico de enfermedades, como el cáncer de próstata clínicamente significativo, en un paciente. También se revelan los métodos para identificar la firma de una enfermedad. Los métodos incluyen la citometría de microflujos (µFCM) para identificar los fenotipos de las partículas y luego utilizar el aprendizaje por máquina para determinar si el paciente tiene la enfermedad de interés o los fenotipos de las partículas de una enfermedad de partículas. El flujo de trabajo de análisis de µFCM que se revela aquí ayuda a identificar la información más útil desde el punto de vista clínico dentro de los datos de µFCM que pueden pasarse por alto en el análisis de compuertas convencional.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3003032A CA3003032A1 (en) | 2018-04-27 | 2018-04-27 | Methods of diagnosing disease using microflow cytometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002768A1 true CL2020002768A1 (es) | 2021-05-28 |
Family
ID=68293427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002768A CL2020002768A1 (es) | 2018-04-27 | 2020-10-26 | Métodos de diagnóstico de enfermedades mediante citometría de microflujos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210048383A1 (es) |
| EP (1) | EP3785014B1 (es) |
| JP (1) | JP7451424B2 (es) |
| CN (1) | CN112313497A (es) |
| AU (1) | AU2019259581B2 (es) |
| BR (1) | BR112020021779B1 (es) |
| CA (2) | CA3003032A1 (es) |
| CL (1) | CL2020002768A1 (es) |
| WO (1) | WO2019204940A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220292363A1 (en) * | 2019-09-02 | 2022-09-15 | Phil Rivers Technology, Ltd. | Method for automatically determining disease type and electronic apparatus |
| JP7428505B2 (ja) * | 2019-11-19 | 2024-02-06 | 富士レビオ株式会社 | コンピュータプログラム、学習モデル生成方法及び情報処理装置 |
| CN113218848B (zh) * | 2021-04-30 | 2022-08-12 | 天津深析智能科技发展有限公司 | 一种判断非特异细胞群的方法 |
| CN113380318B (zh) * | 2021-06-07 | 2023-04-07 | 天津金域医学检验实验室有限公司 | 人工智能辅助流式细胞术40cd免疫表型检测方法及系统 |
| CN114018789A (zh) * | 2021-10-08 | 2022-02-08 | 武汉大学 | 基于成像流式细胞检测和机器学习的急性白血病分型方法 |
| CN115294191B (zh) * | 2022-10-08 | 2022-12-27 | 武汉楚精灵医疗科技有限公司 | 基于电子内镜的标志物尺寸测量方法、装置、设备及介质 |
| JP2024157876A (ja) * | 2023-04-26 | 2024-11-08 | 株式会社日立ハイテク | 情報処理システム、及び情報処理方法 |
| WO2025255587A1 (en) * | 2024-06-07 | 2025-12-11 | Kohler Co. | Systems and methods for generating individual health and wellness insights |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025128A (en) * | 1994-09-29 | 2000-02-15 | The University Of Tulsa | Prediction of prostate cancer progression by analysis of selected predictive parameters |
| US6140065A (en) * | 1997-09-05 | 2000-10-31 | Dianon Systems, Inc. | Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm |
| CA2403874A1 (en) * | 2000-03-28 | 2001-12-06 | Dana-Farber Cancer Institute, Inc. | Molecular database for antibody characterization |
| US20040265874A1 (en) * | 2000-10-17 | 2004-12-30 | Bio-Rad Laboratories, Inc. | Pattern recognition method for diagnosis of systemic autoimmune diseases |
| US20050095611A1 (en) * | 2003-05-02 | 2005-05-05 | Chan Daniel W. | Identification of biomarkers for detecting pancreatic cancer |
| US20060195266A1 (en) * | 2005-02-25 | 2006-08-31 | Yeatman Timothy J | Methods for predicting cancer outcome and gene signatures for use therein |
| US20070009970A1 (en) * | 2005-07-08 | 2007-01-11 | Predicant Biosciences, Inc. | Biological patterns for diagnosis and treatment of cancer |
| US20080133141A1 (en) * | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| US20070255113A1 (en) * | 2006-05-01 | 2007-11-01 | Grimes F R | Methods and apparatus for identifying disease status using biomarkers |
| WO2008064336A2 (en) * | 2006-11-22 | 2008-05-29 | Inivitrogen Corporation | Autoimmune disease biomarkers |
| JP2010256132A (ja) * | 2009-04-23 | 2010-11-11 | Okayama Univ | 糖尿病性腎症の進行度の検出方法及び糖尿病性腎症の進行度の診断キット並びに糖尿病性腎症の進行度の指標となる物質及びその選別方法 |
| AU2012223288B2 (en) * | 2011-03-01 | 2017-03-30 | Yale University | Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) |
| US20130095575A1 (en) * | 2011-10-03 | 2013-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for Fractionation, Analysis and Collection of Microvesicles From Patient Samples |
| MX351626B (es) * | 2012-01-31 | 2017-10-23 | Genomic Health Inc | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. |
| CA2870835C (en) * | 2012-04-19 | 2020-06-16 | Hon Sing LEONG | Method for detecting or monitoring prostate cancer |
| WO2014028494A1 (en) * | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Detecting and treating liver damage |
| CN105101970B (zh) * | 2013-01-10 | 2018-11-20 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| CN105764490B (zh) * | 2013-09-24 | 2020-10-09 | 加利福尼亚大学董事会 | 用于生物测定和诊断的胶囊封装的传感器和感测系统及其制造和使用方法 |
| EA037503B1 (ru) * | 2014-01-21 | 2021-04-05 | Анджариум Байосайенсиз Аг | Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства |
| JP2018505392A (ja) * | 2014-12-10 | 2018-02-22 | ネオゲノミクス ラボラトリーズ, インコーポレイテッド | 自動化されたフローサイトメトリ分析方法及びシステム |
| KR20180030549A (ko) * | 2015-07-22 | 2018-03-23 | 미노믹 인터내셔널 리미티드 | 전립선 질병을 위한 바이오마커 조합 |
| WO2017053592A1 (en) * | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Deep learning in label-free cell classification and machine vision extraction of particles |
| AU2017235661B2 (en) * | 2016-03-18 | 2023-06-08 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| CA3021036A1 (en) * | 2016-04-15 | 2017-10-19 | Octave Bioscience, Inc. | Methods for assessment of multiple sclerosis activity |
| US10914748B2 (en) * | 2016-09-08 | 2021-02-09 | UNIVERSITé LAVAL | Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease |
| US10874610B2 (en) * | 2016-10-19 | 2020-12-29 | Northwestern University | Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer |
| US9934364B1 (en) * | 2017-02-28 | 2018-04-03 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
-
2018
- 2018-04-27 CA CA3003032A patent/CA3003032A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2020560403A patent/JP7451424B2/ja active Active
- 2019-04-26 CA CA3050256A patent/CA3050256C/en active Active
- 2019-04-26 CN CN201980040523.XA patent/CN112313497A/zh active Pending
- 2019-04-26 AU AU2019259581A patent/AU2019259581B2/en active Active
- 2019-04-26 EP EP19792287.5A patent/EP3785014B1/en active Active
- 2019-04-26 US US17/050,799 patent/US20210048383A1/en active Pending
- 2019-04-26 WO PCT/CA2019/050541 patent/WO2019204940A1/en not_active Ceased
- 2019-04-26 BR BR112020021779-4A patent/BR112020021779B1/pt active IP Right Grant
-
2020
- 2020-10-26 CL CL2020002768A patent/CL2020002768A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3785014A1 (en) | 2021-03-03 |
| WO2019204940A1 (en) | 2019-10-31 |
| AU2019259581B2 (en) | 2024-10-17 |
| EP3785014B1 (en) | 2025-06-25 |
| CN112313497A (zh) | 2021-02-02 |
| AU2019259581A1 (en) | 2020-11-26 |
| CA3050256A1 (en) | 2019-10-27 |
| BR112020021779A2 (pt) | 2021-02-23 |
| CA3050256C (en) | 2023-09-05 |
| EP3785014A4 (en) | 2022-01-26 |
| US20210048383A1 (en) | 2021-02-18 |
| CA3003032A1 (en) | 2019-10-27 |
| BR112020021779B1 (pt) | 2023-03-07 |
| JP7451424B2 (ja) | 2024-03-18 |
| JP2021522503A (ja) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| BR112015023883A2 (pt) | método para avaliar planos de tratamento para a aplicação de radioterapia a um paciente; mídia não transitória legível por computador; e sistema para avaliar um plano de tratamento por radiação | |
| MX2016012697A (es) | Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales. | |
| Mirayani et al. | TRANSFORMATIONAL, AUTHENTIC, AND AUTHORITARIAN TYPES OF LEADERSHIP: WHICH ONE IS THE MOST INFLUENTIAL IN STAFFS’PERFORMANCE (A Study On Performance In A Religious School Setting) | |
| MX2019002918A (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. | |
| BR112015012507A8 (pt) | método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase | |
| AR101549A1 (es) | Sistema y método para informar sobre la calidad de un perforador direccional | |
| AR092423A1 (es) | Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas | |
| Gariboldi et al. | Evaluation of surgical aid of methylene blue in addition to intraoperative gamma probe for sentinel lymph node extirpation in 116 canine mast cell tumors (2017–2022) | |
| IN2013MU01495A (es) | ||
| Pentenero et al. | Microbiopsy a first‐level diagnostic test to rule out oral dysplasia or carcinoma in general dental practice | |
| Liu et al. | Deep learning based multi-organ segmentation and metastases segmentation in whole mouse body and the cryo-imaging cancer imaging and therapy analysis platform (CITAP) | |
| CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto | |
| Siegel et al. | Evaluation of the vulvar cancer histology code reported by central cancer registries: importance in epidemiology | |
| Sarkar et al. | The case for microcredit: does It improve maternal and child health and wellbeing | |
| Murray et al. | Human epidermal growth factor receptor 2 testing by fluorescent in situ hybridization: positive or negative? American Society of Clinical Oncology/College of American Pathologists guidelines 2007, 2013, and 2018 | |
| Mibtadin | THE URBAN SUFISM, SOCIAL MOVEMENT AND THE ‘SMILING’ISLAM: A case study of “Hubbun Nabi” Kartasura, Sukoharjo | |
| CL2022000817A1 (es) | Dispositivo de clasificación automatizada de organismos y método de uso | |
| DE602006018458D1 (de) | Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose | |
| Mehrotra et al. | Integrated Cancer Screening Strategies in India | |
| Hills et al. | A prospective study into the incidence of aspiration and dysphagia in acute stroke patients admitted to Beaumont Hospital | |
| Galetta et al. | Validation of multiplex immunofluorescence for use in analysis of tumour infiltrating lymphocytes | |
| Seidl | Evidence-Based and Data-Driven Approaches to Corporate Health Management | |
| Wu et al. | Advancements in Image-Based Artificial Intelligence in the Diagnosis and Treatment of Head and Neck Squamous Cell Carcinoma: A Narrative Review | |
| Thompson | Guest editorial: Furthering our understanding of positive urine cultures in dogs |